FGAM
NTLA icon

Financial Gravity Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Financial Gravity Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-41
Closed -$22 – 1591
2023
Q2 		$22 Buy
+41
New +$1.66K ﹤0.01% 1483
2023
Q1 		– Sell
-35
Closed -$19 – 1481
2022
Q4 		$19 Buy
+35
New +$1.66K ﹤0.01% 1323

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Financial Gravity Asset Management's NTLA Position: Q3 2023 in Review

Financial Gravity Asset Management sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 41 shares — an estimated $22 sold.

Financial Gravity Asset Management first reported a position in NTLA in Q4 2022 and held it in 2 quarters. The position peaked at $22 in Q2 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

  • Financial Gravity Asset Management reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Financial Gravity Asset Management sold 41 Intellia Therapeutics shares in Q3 2023, an estimated $22.
  • Financial Gravity Asset Management first reported a position in Intellia Therapeutics in Q4 2022 and held it in 2 quarters.
  • Financial Gravity Asset Management's Intellia Therapeutics position peaked at $22 in Q2 2023.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Financial Gravity Asset Management's 13F filing for Q3 2023, filed 16 Nov 2023.